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Abstract
Joubert syndrome (JBTS) is the archetypal ciliopathy caused by mutation of genes encoding ciliary proteins leading to multi-
system phenotypes, including a cerebello-retinal-renal syndrome. JBTS is genetically heterogeneous, however mutations in
CEP290 are a common underlying cause. The renal manifestation of JBTS is a juvenile-onset cystic kidney disease, known as
nephronophthisis, typically progressing to end-stage renal failure within the first two decades of life, thus providing a poten-
tial window for therapeutic intervention. In order to increase understanding of JBTS and its associated kidney disease and to
explore potential treatments, we conducted a comprehensive analysis of primary renal epithelial cells directly isolated from
patient urine (human urine-derived renal epithelial cells, hURECs). We demonstrate that hURECs from a JBTS patient with
renal disease have elongated and disorganized primary cilia and that this ciliary phenotype is specifically associated with an
absence of CEP290 protein. Treatment with the Sonic hedgehog (Shh) pathway agonist purmorphamine or cyclin-dependent
kinase inhibition (using roscovitine and siRNA directed towards cyclin-dependent kinase 5) ameliorated the cilia phenotype.
In addition, purmorphamine treatment was shown to reduce cyclin-dependent kinase 5 in patient cells, suggesting a conver-
gence of these signalling pathways. To our knowledge, this is the most extensive analysis of primary renal epithelial cells
from JBTS patients to date. It demonstrates the feasibility and power of this approach to directly assess the consequences of
patient-specific mutations in a physiologically relevant context and a previously unrecognized convergence of Shh agonism
and cyclin-dependent kinase inhibition as potential therapeutic targets.
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Introduction
Joubert syndrome (JBTS) is a ciliopathy syndrome which is char-
acterized most often by cerebellar defects and retinal dystrophy.
Additional phenotypes in other organ systems frequently occur,
including the cystic kidney disease nephronophthisis (NPHP) (1).
Positional cloning strategies and whole exome sequencing have
successfully identified numerous underlying genetic causes for
JBTS. CEP290 (alias NPHP6) mutations underlie JBTS type 5 (2,3)
and are the commonest genetic lesion associated with a
cerebello-oculo-renal phenotype (4). However, clinical pheno-
types associated with CEP290 mutations may be diverse and in-
clude isolated Leber congential amaurosis (LCA) (5,6), Meckel-
Gruber syndrome (7,8) and Bardet-Biedl syndrome (9).
CEP290 encodes a 290 kDa centrosomal protein that is co-lo-
calized with gamma-tubulin at the basal body during inter-
phase (2). During cell division CEP290 has a dynamic
localization (2). Elegant work in Chlamydomonas has revealed
that CEP290 is an integral part of the transition zone, the speci-
alized region at the most proximal part of the cilium, which to-
gether with transition fibers forms the ciliary gate. In murine
photoreceptor cells Cep290 localizes to the connecting cilium
(2), a structure which represents a specialized transition zone
that extends between the inner and outer segments of the
photoreceptor cell (10).
We previously reported a murine model of JBTS using LacZ
gene trapping of Cep290. The mice developed cystic kidney dis-
ease as well as retinal dystrophy and brain defects, recapitulat-
ing the human phenotype. Using this model, we identified
abnormal Sonic hedgehog (Shh) signalling as an early feature of
cystic kidney disease, preceding detectable Wnt aberration (11).
Treatment with purmorphamine, which is a Hedgehog (Hh)
pathway activator and facilitates the translocation of
Smoothened into the primary cilia (12), partially rescued the
phenotype of mutant Cep290LacZ/LacZ spheroids and is a poten-
tial, though possibly toxic therapy for ciliopathies. It is notewor-
thy that purmorphamine has other reported actions including
the regulation of certain cell cycle control genes and promoting
cellular proliferation (12,13). CEP290 mutations have not been
directly related to cell cycle defects, although a related ciliop-
athy gene CEP164 (alias NPHP15) regulates cell cycle progression
(14) and is implicated in DNA damage response signaling (15).
Our earlier work reported that Cep290 depletion, in murine kid-
ney cells and zebrafish embryos, also causes an increase in DNA
damage. This was associated with an increase in cyclin-depen-
dent kinases 1 and 2 and prompted the treatment of murine
Cep290-deficient cells with roscovitine, a CDK inhibitor, which
rescued DNA damage and restored cellular phenotypes, includ-
ing spheroid formation phenotypes (16). Pharmacological treat-
ments for human CEP290 ciliopathies are still lacking and
therefore we aimed to explore potential drug treatments using
human urine-derived renal epithelial cells (hURECs) from pa-
tients with CEP290 mutations.
Here we characterize hURECs from a JBTS patient with
CEP290 mutations and a cerebello-retinal-renal phenotype in
order to establish the ability of ex vivo therapies to rescue ciliary
phenotypes. Cilia from this JBTS patient were abnormally long
with an apparent mismatch in axonemal and ciliary membrane
length. This was in comparison to hURECs derived from wild
type controls and also from a patient with isolated LCA second-
ary to CEP290 mutations, in whom there was no renal involve-
ment. We used purmorphamine to rescue cilia defects, and
noted a decrease in cell mitosis and cyclin-dependent kinase 5
(CDK5) levels in response to this therapy. This provided a
rationale for exploring the use of siRNA directed towards CDK5
and roscovitine as a potential treatment for CEP290 ciliopathy.
Results
We studied a non-consanguineous English family in whom two
children (JBTS II: 1 and JBTS II: 2) were severely affected with
JBTS (Fig. 1A), manifesting as early onset nystagmus and LCA re-
sulting in visual loss (Table 1). Both siblings have severe devel-
opmental delay, cystic kidney disease typical of NPHP (Fig. 1F)
and progressive renal failure leading to end stage renal disease
(ESRD) before 5 years of age. The MRI brain in JBTS II: 1 demon-
strated the typical molar tooth sign (including cerebellar vermis
hypoplasia and thick and abnormally oriented superior cerebel-
lar peduncles) and enlargement of the fourth ventricle (Fig. 1G,
H). Panel sequencing of ciliopathy genes allowed the identifica-
tion of pathogenic compound heterozygous mutations in
CEP290 in both affected children (c.2817G>T; p.K939N and
c.2848insC; p.Q950Pfs*6) leading to a predicted truncated pro-
tein, with each allele segregating from either parent (Table 1,
Fig. 1A, B, C). Additional heterozygous (non-pathogenic) alleles
in known ciliopathy genes were also detected including NPHP3:
rs772079066 and DNAH1: rs536088715. A full list of alleles is
available (Supplementary Material, Table S1, S2 and S3). qPCR of
JBTS II: 2 RNA confirmed equal transcript expression at a 5’
(exon 6–7) and 3’ (exon 48–49) target but Western blotting using
an antibody directed towards the C-terminus of CEP290 con-
firmed loss of full-length protein (Fig. 1D, E).
Prior to the onset of ESRD in patient JBTS II: 2, we were suc-
cessful in culturing hURECs which were compared to wild type
age matched controls (Fig. 2A, B). These primary, non-
transformed renal epithelial cells provide an opportunity to
carry out detailed analysis ex vivo of primary cells from JBTS pa-
tients to dissect the CEP290 disease phenotype in this family.
Quantification of low power immunofluorescence imaging of
cells (Fig. 2C, D) revealed a significant difference in the mean cil-
iation rates (64% in wild-type cells versus 41% in cells from JBTS
II: 2; Supplementary Material, Fig. S1a). The cilia in JBTS II: 2
were elongated (Fig. 2D) prompting more detailed imaging.
Scanning electron microscopy (SEM) imaging (Fig. 2E, F) con-
firmed elongated primary cilia in patient JBTS II: 2 cells (mean
length 7.7 mm compared to 4.9 mm in wild type) with an abnor-
mality at the distal tip (Fig. 2F). Median lengths of cilia were
4.880 mm in wild type and 7.665 mm in JBTS II: 2 cells
(Supplementary Material, Fig. S2h). Under SEM, JBTS II: 2 cilia
(n¼ 10) were elongated but displayed a range of phenotypes in-
cluding three that were morphologically normal, five with ab-
normalities of the ciliary tip (as seen in Fig. 2F) and two with an
increase in their tortuosity, defined as greater than four bends
or kinks in the ciliary axoneme. Cilia diameter, measured under
SEM was comparable, with mean diameters of 180 nm in JBTS II:
2 versus 190 nm in wild type cilia. Length and ciliary morphol-
ogy defects were confirmed by high power immunofluorescence
imaging (Fig. 2G, H), using antibodies directed towards both
alpha-acetylated tubulin (Acet Tub) to identify ciliary axonemes
and ADP-ribosylation factor-like protein 13B (ARL13B) (17) a cili-
ary membrane-associated protein. The observed length differ-
ence using these two antibodies however revealed an
uncoupling between the regulation of axonemal and cilia mem-
brane length (Fig. 2I, J, K). The mean length of cilia as identified
using Acet Tub increased from 3.5 mm in wild type to 5.4 mm in
JBTS II: 2, but from 4.0 mm in wild type to 7.7 mm in JBTS II: 2
when identified using ARL13B antibodies to identify cilia
2 | Human Molecular Genetics, 2017, Vol. 00, No. 00
Downloaded from https://academic.oup.com/hmg/article-abstract/doi/10.1093/hmg/ddx347/4110400/A-human-patient-derived-cellular-model-of-Joubert
by University of Newcastle user
on 02 October 2017
membrane. Median cilia lengths also differed between Acet Tub
and ARL13B (Supplementary Material, Fig. Sh) The mean differ-
ence in cilia length in JBTS II: 2 patients per cilium, as measured
using ARL13B length minus Acet Tub length was 0.4 mm in wild
type versus 2.4 mm in JBTS II: 2, with a variable rather than con-
stant difference in length (Fig. 2K). Additional antibody staining
directed towards the transition zone protein CEP162, and peri-
centrin, an integral component of the pericentriolar material,
did not show mislocalization in JBTS II: 2 cells (Supplementary
Material, Fig. S2a, b, c, d). Antibodies directed towards the intra-
flagellar transport protein 88 (IFT88) an axonemal protein
showed increase in cilia length in JBTS II: 2 cells, with
comparable cilia lengths to those measured with alpha-
acetylated tubulin (Supplementary Material, Fig. S2e–h).
To demonstrate that these morphological defects are pri-
marily due to a loss of function of CEP290 in the JBTS patient’s
cells we sought to treat wild type hURECs with siRNA directed
towards CEP290. siRNA treatment revealed a ciliary phenotype
of increased length, resembling the patient II: 2’s cilia (Fig. 3A).
CEP290 siRNA achieved a significant knockdown of full length
CEP290 protein, as determined by Western blot (Fig. 3B). We ob-
served an increase in cilia length, as determined both by the cil-
iary membrane marker ARL13B and alpha acetylated tubulin
(Fig. 3C).
Figure 1. Pedigree, genetic and clinical imaging data of JBTS family H67. (A) Pedigree diagram showing two affected siblings (squares, males; circles females).
(B) Sequence chromatograms showing compound heterozygous changes in CEP290 c.2817G>T; p.K939N (predicted to affect splice donor site) and c.2848insC;
p.Q950Pfs*6. (C) Domain structure of CEP290 protein (2479 amino acids) with predicted coiled coil domains (CC) numbered and shown in yellow; tropomyosin homology
domain (TM), RepA/Repþ protein KID (KID); bipartite nuclear localization signal (NLS_BP); ATP/GTP-binding site motif A (P-loop). The extent of homology with SMC pro-
teins is indicated by an orange bar. The predicted truncation of CEP290 at amino acid positions 939 and 950 are shown. (D) qPCR showing relative level of CEP290 tran-
script measured at the 5’ (Exon 6-7) and the 3’ (Exon 48-49) ends. RNA samples from patient II: 2 hURECs show a similar level of transcript to wild type (WT, normalized
to 1) indicating a lack of nonsense mediated decay (Standard error of means indicated by bars). Experiments performed in triplicate. (E) Western blot (cropped image)
showing reduced expression of full-length wild type CEP290 protein from hURECs derived from II: 2 using a C-terminal directed CEP290 antibody. Experiments
performed in triplicate. (F) Renal ultrasound scan of II: 2 showing cystic change within the kidney. (G) Axial MRI image of brain showing molar tooth sign in II:
1. (H) Sagittal MRI image of brain shows hypoplasia of the cerebellar vermis and enlarged mid-fourth ventricle (white arrows) in II: 1.
Table 1. Clinical characteristics of JBTS family (H67)
JBTS II: 1 JBTS II: 2
Nucleotide alterations Het c.2817G>T Het c.2817G>T
Het c.2848insC Het c.2848insC
Alteration in coding sequence Het p.K939N (splice donor site mutation) Het p.K939N
Het p.Q950Pfs*6 (frameshift mutation) Het p.Q950Pfs*6
Exon (segregation) 25(M) 25(M)
26 (P) 26 (P)
Renal USS Increased echogenicity, corticomedullary cysts,
loss of corticomedullary differentiation
Increased echogenicity, corticomedullary cysts,
loss of corticomedullary differentiation
ESRD (years, months) ESRD (1 y, 11 months) ESRD (4 y, 9 months)
Ocular symptoms
(age of onset, months)
NY (3 months) NY (2 months)
CA (6 months) CA (2 months)
Central Nervous symptoms Seizures, global developmental delay Developmental delay
MTS
Other Scoliosis
CA, congenital amaurosis (bilateral); ESRD, end-stage renal disease; Het, heterozygous in affected individual; M, Maternal mutation identified; MTS, molar tooth sign;
N/A, no data available; NY, nystagmus; P, Paternal mutation identified.
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Figure 2. Renal epithelial cilia derived from a patient with CEP290 mutations demonstrate length and morphological defects. (A and B) Wild type and patient JBTS II: 2
hURECs form a typical cobblestone epithelial cell layer when grown in 2D culture (Scale bar 100 mm). (C and D) Wild type and patient JBTS II: 2 hURECs following immu-
nofluorescence imaging using anti-ARL13B (green) to identify ciliary membrane and DAPI to identify nuclei. (Scale bar 50 mm). (E and F) Scanning electron microscopy
(SEM) images reveal abnormally long cilia in patient JBTS II: 2 cells with distal tip anomalies (Scale bar 2 mm). (G and H) Immunofluorescence staining using anti-alpha-
acetylated tubulin (red) to identify axoneme and anti-ARL13B (green) to identify ciliary membrane in wild type and JBTS II: 2 cells (Scale bar 5um). (I) Dot plot with
means (4.7 versus 7.7 mm) to show ciliary length measured by SEM. (n¼10 for each group, *P < 0.05, Unpaired Student’s t-test). (J) Dot plots with means indicated to
show ciliary length measured by immunofluorescence imaging using antibodies against alpha-acetylated tubulin (Acet Tub) and ARL13B. (n¼49 for WT cilia and n¼49
for II: 2 cilia, *P < 0.0001, Unpaired Student’s t-test). (K) Dot plots with means indicated to show the increase in cilia length of each cilia (data from panel j) as deter-
mined by measuring axonemal length under immunofluorescence imaging using antibodies against alpha-acetylated tubulin (Acet Tub) and ARL13B. (*P < 0.0001,
Unpaired Student’s t-test).
4 | Human Molecular Genetics, 2017, Vol. 00, No. 00
Downloaded from https://academic.oup.com/hmg/article-abstract/doi/10.1093/hmg/ddx347/4110400/A-human-patient-derived-cellular-model-of-Joubert
by University of Newcastle user
on 02 October 2017
The finding of abnormally elongated cilia in JBTS patients and
following siRNA mediated knockdown of CEP290 are in contrast
to the findings in another unrelated family with CEP290 muta-
tions. In this family there was a single affected 14 year old child
with a phenotype limited to LCA, without brain or renal involve-
ment (LCA II: 2). At this age, with documented normal renal func-
tion the development of a NPHP phenotype in this individual is
extremely unlikely (18). Here the LCA phenotype was confirmed
to be secondary to biallelic mutations in CEP290 (c.297þ1G>T and
c.4661_4663delAAG; p.Q1554del) (Supplementary Material, Fig.
S3a, b, c). Interestingly, despite biallelic mutations, CEP290 pro-
tein was evident on Western blotting of kidney protein derived
from hURECs (Supplementary Material, Fig. S3d) and hURECs iso-
lated from patient LCA II: 2 showed no significant reduction in cil-
iation rates or cilia length abnormality (Supplementary Material,
Fig. S3e–j). These findings add some specificity to the elongated
ciliary length seen in renal epithelial cells in CEP290 patients with
renal phenotypes.
Our previous work has implicated abnormalities in the Hh
pathway in CEP290 disease mechanisms (11). Using hURECs
from patient JBTS II: 2 we were able to show a rescue of both the
ciliary length, with a complete rescue of increased tortuosity
and bulbous phenotypes seen using SEM (n¼ 10) and restoration
of the normal relationship between the axoneme identified by
alpha-acetylated tubulin and ARL13B positive ciliary membrane
following treatment with purmorphamine (Fig. 4A–D).
Treatment with purmorphamine did not affect overall percent-
age ciliation rates in mutant cells (Supplementary Material, Fig.
S1a). Conversely, treatment of wild-type hURECs with the Hh
antagonist HPI-4 replicated the abnormally long ciliary pheno-
type, with increased tortuosity seen in 3 out of 10 cilia imaged
using SEM. No cilia with bulbous tips were observed and there
was no excess in ciliary membrane length when compared to
axonemal length, using immunofluorescence microscopy, sug-
gesting that additional factors contribute to the uncoupling of
the axonal to cilia length caused by CEP290 mutation
(Supplementary Material, Fig. S4a–f).
It is known that Hh agonists such as purmorphamine affect
different molecular pathways, in particular proliferation, albeit
in a cell type specific manner. For example, purmorphamine
may in some cases promote proliferation (19) and in others sup-
press proliferation (20). The study of murine Cep290 mutant cell
lines has suggested that CDK inhibition may have positive ef-
fects in JBTS cellular phenotypes (16). In addition, murine mod-
els of polycystic kidney disease (21) suggest that CDK inhibition
may be therapeutic option for treating cystic kidney disease.
hURECs derived from JBTS II: 2 showed a small increase in SHH
expression as determined by quantitative PCR in response to
treatment with purmorphamine (Fig. 5A) which was not signifi-
cantly different from the response to purmorphamine in control
hURECs. There was a lack of response in GLI1, a Hh pathway ef-
fector, following purmorphamine treatment, which was not sig-
nificantly different in both wild type and JBTS II: 2 hURECs (Fig.
5A). During renal development (22) and, as was shown recently,
during renal fibrosis, SHH signalling acts in a paracrine fashion.
In adult murine kidney tissue, expression of Shh was limited to
the tubular epithelium of the papillary collecting duct whilst its
effector Gli1 was expressed in interstitial cells only (23).
Therefore hUREC cells alone may lack the ability to mediate in-
creases in GLI1. The lack of GLI1 response in hUREC cells also
raises the possibility that purmorphamine may be acting in an
alternate pathway to rescue the cilia phenotype. We noted that
treatment with purmorphamine reduced the percentage of cy-
cling cells in mutant hURECs (Supplementary Material, Fig. S1b)
and that CDK5 protein levels were reduced in both wild type
and JBTS II: 2 cells following purmorphamine treatment (Fig.
5B). This suggests either a convergence of Hh and CDK path-
ways or that purmorphamine rescue was mediated by CDK inhi-
bition. To investigate a role for CDK5 in cilia length regulation
we show that siRNA directed towards CDK5 is able to rescue the
increased cilia length phenotype in hURECs from JBTS II: 2 (Fig.
5C, D, E). This provided a rationale for using direct CDK inhibi-
tion in CEP290 mutant hURECs. Mutant cilia from JBTS II: 2 re-
sponded to treatment with the CDK inhibitor roscovitine
showing a significant reduction in ciliary length, as measured
by ARL13B (Fig. 5F, G) whilst overall percentage ciliation rates
were unchanged (Supplementary Material, Fig. S1a). When cili-
ary axonemes were measured with both alpha-acetylated tubu-
lin and ARL13B we show that despite the reduction in cilia
length the mismatch in measured length remained evident
(Supplementary Material, Fig. S5a, b). The response to both pur-
morphamine and roscovitine treatment was also confirmed in
wild type hURECs treated with siRNA directed towards CEP290.
The abnormally long cilia, measured by ARL13B, produced by
siRNA CEP290 knockdown cells was rescued by both purmorph-
amine and roscovitine treatment (Fig. 5H) whilst overall cilia-
tion rates remained unchanged (Supplementary Material, Fig.
S5c, d).
Figure 3. CEP290 knockdown by siRNA in hURECs reveals a ciliary length pheno-
type. (A) Immunofluorescence imaging of cilia identified by anti-alpha-acety-
lated tubulin (Acet Tub red) and anti-ARL13B (ARL13B, green). Scale bar 10lm.
(B) Western blot (cropped image) showing loss of full length CEP290 protein in
wild type hURECs following knockdown of CEP290 using directed siRNA. (C). Dot
plots to show ciliary length in wild type (WT) untreated and siRNA CEP290
treated hURECs measured by immunofluorescence imaging using antibodies
against alpha-acetylated tubulin (Acet Tub) and ARL13B. (n¼47 for WT cilia and
n¼52 for siRNA treated cilia, *P < 0.0001, Unpaired Students t-test).
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Discussion
The clinical phenotype of CEP290 mutations, as with that of
other JBTS and related ciliopathy genes, consists of a broad
spectrum (24). However, data are lacking concerning detailed
cellular, and in particular cilia phenotypes of JBTS mutations in
patients. By studying primary, non-transformed renal epithelial
cells derived from a JBTS patient with a cerebello-retinal-renal
phenotype carrying pathogenic compound heterozygous
CEP290 mutations, we observed abnormally long cilia with a
mismatch in cilia staining between alpha-acetylated tubulin, an
axonemal protein, and ARL13B, a ciliary membrane associated
protein. An increased ciliary length phenotype in hURECs was
not seen in a patient with LCA limited CEP290 associated dis-
ease, suggesting tissue specific cilia defects may be seen in vivo.
It has been previously demonstrated that CEP290 protein lo-
cated within the transition zone can bridge between the cilia
membrane and the axoneme as it directly binds to cellular
membranes through an N-terminal domain and to microtu-
bules through a domain located within its myosin-tail homol-
ogy domain (25). Loss of a functional CEP290 protein, as in JBTS
II: 2 patient’s hURECs, might therefore directly lead to an uncou-
pling of cilia membrane and axoneme. Importantly we could re-
capitulate this elongated cilia phenotype by using siRNA
mediated knockdown of CEP290 in wild type hURECs, thus un-
equivocally implicating CEP290 in this process. To our knowl-
edge, this is the first time that loss of function of CEP290 has
been shown to lead to an elongation of cilia, rather than an im-
pairment of cilia formation which has been shown in murine
(26) and cellular models (27).
Control of primary ciliary length is an important and dy-
namic process and is intimately related to ciliary signaling (28).
Cilium extension, which occurs from the basal body, and main-
tenance of length requires intraflagellar transport (IFT). IFT is a
complex process reliant upon molecular motors moving along
the microtubules of the ciliary axoneme (29). Defects in ciliary
length are associated with severe developmental diseases, in-
cluding JBTS. Indeed, it is intriguing to note that several renal
cystic diseases have been associated with long cilia. Kidney tu-
bules and cultured renal tubular cells from Bbs4-null mice dis-
played elongated cilia with an intact microtubular structure
following prolonged culture (30) whilst jck mice (Nek8 mutation)
also revealed long cilia (31,32). Kidney tissues from a foetus af-
fected with MKS3 mutations displayed longer cilia than control
tissue, as measured by alpha-acetylated tubulin staining (33).
Cells depleted of KIF7 (JBTSF12) and KIAA0556 (JBTS26) also
have extended axonemes (34,35). The KIF7 deficient cilia were
both long and had irregular bends along their length and cilia
from fibroblasts derived from ovine kidney with mutations in
TMEM67 (JBTS6) have abnormally long cilia, with bulbous de-
fects along the axonemes and sharp kinks (36).
It is clear from these and other reported models of JBTS that
alterations of cilium morphology and/or length can have dra-
matic functional implications. Specifically, elongated cilia take
longer to be dismantled, which can influence the timing of the
re-entry of the cell into cell cycle (37).
We show that purmorphamine is able to rescue the morpho-
logical defects of a JBTS patient’s primary cilia. These data, en-
couragingly, indicate that ciliopathies are treatable even in
hURECs derived from patients at an advanced stage of kidney
Figure 4. Rescue of CEP290 mutant cilia length defects in hURECs using purmorphamine treatment. (A) Scanning electron microscopy (SEM) images showing cilia in pa-
tient JBTS II: 2 hURECs before and after purmorphamine (Pur) treatment. Scale bar 2 mm. (B) Dot plots with means showing ciliary lengths measured by SEM in wild
type (WT) and patient JBTS II: 2 hURECs before and after treatment with purmorphamine (Pur). (n¼10 for each group, *P < 0.0001, Unpaired Student t-test; n.s. not sig-
nificant). Untreated WT and II: 2 cilia lengths are replicated from Figure 2I. (C) Immunofluorescence images showing cilia in patient JBTS II: 2 hURECs before and after
purmorphamine treatment. Scale bar 5 mm. (D) Dot plots with means to show ciliary length determined by immunofluorescence imaging in wild type (WT) patient JBTS
II: 2 hURECs untreated and treated with purmorphamine using anti-alpha-acetylated tubulin (Acet Tub) and anti-ARL3B (ARL13B). (Cilia counts n¼36 for WT, n¼ 35 for
II: 2 untreated and n¼40 for II: 2 treated; *P < 0.0001, ANOVA).
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disease. However, important caveats include the fact that cil-
ium length is not an established biomarker of disease and that
purmorphamine treatment has not yet been directly tested us-
ing in vivo models of Cep290 knockdown. It also has not been
definitively shown that hURECs represent the most relevant cell
type to study CEP290-related kidney disease, although these
cells are a highly accessible model, and are mostly collecting
duct in origin, expressing aquaporin-2 (38,39). It is important to
Figure 5. CDK5 inhibition via purmorphamine, siRNA and roscovitine rescues ciliary phenotype in CEP290 deficient cells. (A) Expression of SHH and GLI1 RNA tran-
scripts in hURECs from wild type controls and JBTS II: 2 before and after treatment with purmorphamine (Pur). Expression was normalized to control genes GAPDH and
HPRT. Error bars indicate standard deviation; n.s., not significant, ANOVA. Experiments performed in triplicate. (B) Western blot (cropped image) of CDK5 levels follow-
ing treatment with purmorphamine in wild type and JBTS II: 2 hURECs. Quantification (right) normalized to GAPDH expression. Experiments were performed in tripli-
cate. (C) Western blot (cropped image) of siRNA CDK5 and control (CTRL) siRNA treatment of JBTS II: 2 and wild type (WT) hURECs shows a reduction in CDK5 protein
expression. Beta-actin (B-ACTIN) loading control. Experiments performed in triplicate. (D) Low power immunofluorescence images (alpha-acetylated tubulin, red;
ARL13B green, DAPI, blue) of hURECs from JBTS II: 2 after treatment with control siRNA (siCTRL) or siRNA CDK5 (siCDK5) (scale bar 10 mm). (E) Dot plot with means to
show quantification of cilia length of hURECs from JBTS II: 2 (shown in d) after treatment with control siRNA (siCTRL) or siRNA CDK5 (siCDK5) (*P < 0.001, unpaired
Student’s t-test, n¼129 siCTRL, n¼95 siCDK5, median values siCTRL 10.43 mm, siCDK5 7.356 mm). (F) High power immunofluorescence images (alpha-acetylated tubu-
lin, red; ARL13B green, DAPI, blue) of hURECs from JBTS II: 2 before and after treatment with roscovitine. Scale bar 5 mm. (G) Dot plot with means to show quantification
of cilia length using ARL13B in wild type (WT, n¼48), wild type treated with roscovitine (WT þ Rosc, n¼21), JBTS II: 2 hURECs (n¼48) and JBTS II: 2 treated with roscovi-
tine (Ros, n¼ 34) (n.s. not significant, *P ¼ 0.004, unpaired Student’s t-test). (H) Dot plot with means to show quantification of cilia length using ARL13B in control siRNA
(siCTRL, n¼ 109), siRNA CEP290 (siCEP290, n¼100), siRNA CEP290 þ purmorphamine (siCEP290þPur, n¼95) and siRNA Cep290 þ roscovitine (siCEP290 þ Ros, n¼162)
treated hURECs (*P < 0.0001, ANOVA).
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note that the typical kidney disease progression in JBTS patients
allows a therapeutic window for intervention with targeted
therapies. We show that whilst purmorphamine is a known Hh
agonist, treatment of hURECs with this compound result in no
changes to canonical Hh target genes but instead produce
changes in cell cycle and a reduction in CDK5 levels, suggesting
convergence of Hh and CDK pathways. We demonstrate that
treatment with either siRNA directed towards CDK5 or roscovi-
tine, a potent inhibitor of CDK5, restores cilia length to JBTS
hURECs. This finding seen using JBTS patient kidney cells, is
similar to that of the burgeoning number of mouse models that
show a positive response to CDK inhibition. Renal cystic kidney
disease in jck mice, which also exhibit long cilia, can be rescued
by CDK inhibition with roscovitine and its more potent and se-
lective analogue S-CR8 (40) as can the cystic phenotype in cpk
(Cystin) mice (21). Indeed, Pkd1 conditional knock-out mice also
responded to treatment with roscovitine and S-CR8. With the
cautions of the interpretation of hURECs and the use of cilia
length as a biomarker of cystic kidney disease noted, our data
suggests that CEP290 defects in renal tubular epithelium may be
responsive to drug treatments. The morphological rescue in re-
nal cells from patient JBTS II: 2 allows some optimism in target-
ing and rescuing the renal lesions in CEP290 deficient renal
epithelial cells.
It is intriguing to note the similarity between the cilia pheno-
type we describe for patient-derived renal epithelial cells carry-
ing CEP290 mutation and the jck mouse, caused by mutation of
Nek8. The increased tortuosity seen under SEM in both cases is
remarkably similar and suggests that the ciliary tip lacks a
proper tubulin structure in both cases. To date these unrelated
genes have not been mechanistically linked, in fact they show
quite different localizations with Cep290 protein found in basal
bodies and Nek8 protein located along the length of the cilium
(41). In fact, Nek8 seems to be localised to a subciliary domain
known as the inversin compartment (42). However, the positive
response of both Cep290 and Nek8 mutant cells (and other ciliop-
athy models as described above) to CDK inhibitors suggests a
common aetiology. Furthermore, our data indicate that Hh ago-
nism with purmorphamine, previously shown to restore cellu-
lar phenotype in the case of Cep290 mutation, may be acting, at
least in part, through CDK inhibition. This is underscored by the
recent demonstration that a reduction in ciliary length, brought
about by CDK inhibitors, attenuates cystic kidney disease in
murine nephronophthisis (43) and that our data, obtained from
patient-derived renal epithelial cells, indicates that patient cells
respond in the same way.
In conclusion, culturing of hURECs from JBTS patients with a
cerebello-retinal-renal phenotype with CEP290 mutations has
revealed an elongated cilia phenotype which is rescuable by
both purmorphamine, siRNA directed towards CDK5 and the
CDK inhibitor roscovitine. We show for the first time that pur-
morphamine and CDK inhibition treatments have similar phe-
notypical effects on patient-derived primary kidney cells that
seem to reflect a convergence of pathways. This helps to focus
the possibilities for therapeutic manipulation of renal
ciliopathies.
Materials and Methods
Clinical and DNA sequencing
All patients consented to this study. Ethical approval was ob-
tained from the National Research Ethics Service (NRES)
Committee North East (14/NE/1076). Following informed and
written consent, urine and blood samples were obtained from
an affected 4 year-old boy with clinical JBTS with a retinal, renal,
and cerebellar phenotype, a 12 year old boy with isolated LCA
and his unaffected sibling and healthy gender and age-matched
controls. Ethical approval was obtained from the National
Research Ethics Service (NRES) Committee North East (14/NE/
1076). All methods were performed in accordance with the rele-
vant ethical guidelines and regulations.
Sequencing of ciliopathy genes was performed by applying
exon-enriched NGS targeting up to 1, 221 genes associated with
cilia including all known genes associated with ciliopathies
(“ciliome sequencing”) (44–46) and consecutive barcoded NGS
on a SoliD5500 (Life tech) or HiSeq 2500 (Illumina) platform.
Confirmation of mutations and segregation analysis was per-
formed on other family members following informed consent
using Sanger sequencing, using exon specific primers.
hUREC isolation, FACS analysis and culture
Human urine-derived renal epithelial cells (hURECs) were iso-
lated from urine collected from patient II: 2 before his onset of
ESRD, and healthy age-matched donors and cultured as previ-
ously described (2,39). To quantify cell cycle phase distribution,
WT and JBST II: 2 cells were fixed in 70% ethanol and treated
with RNAse and stained with propidium iodide. The cells were
measured using a 5-laser BD LSRII system, measuring PI emis-
sion from a 561 nm yellow/green laser in the 610/20 filter. Data
was analyzed using BD FACSDiva software.
Real-time PCR
RNA was extracted using Trizol (Thermo Fisher Scientific) accord-
ing to the manufacturer’s instructions, and quantified using a
NanoDrop 2000 Spectrophotometer (Thermo Fisher Scientific).
1ug of RNA was reverse-transcribed using an Oligo-dT primer
and SuperScript III Reverse Transcriptase (Thermo Fisher
Scientific). The resulting cDNA was diluted 10-fold in nuclease-
free water. Real-time PCR was carried out in a 10ul reaction vol-
ume containing the following: 0.5ul of each primer (10uM stock)
or 0.5ul PrimeTimeVR qPCR probe-based assay (IDT) with 0.5ul wa-
ter, 4ul of cDNA and 5ul of either 2 SYBR Green PCR Master Mix
(Applied Biosystems) or 2 PrimeTimeVR Gene Expression Master
Mix (IDT). The PCR was run using a QuantStudioTM 7 Flex Real-
Time PCR System (Applied Biosystems) using the following
settings: 95 C for 20 s, followed by 40 cycles of 95 C for 1 s
60 C for 20 s. The PrimeTimeVR assays used were as follows:
GAPDH - Hs.PT.39a.22214836, HPRT1-Hs.PT.58.20881146, CEP290 -
Hs.PT.58.3248011 and Hs.PT.58.2324908. Primer sequences are
available on request.
Western blotting
48 h after plating or transfection, renal epithelial cells were
lysed and proteins were extracted with a 4 M urea, 125 mM Tris
pH 6.8, 4% SDS, 10% glycerol, 5% b-mercaptoethanol and 0.02%
bromophenol blue solution. Protein samples were heated to
95 C for 5 min, spun at 16 000 rcf for 5 min and resolved by SDS-
PAGE. Proteins were transferred to a nitrocellulose membrane.
The membranes were blocked in TBST (Tris-buffered saline,
0.1% Tween-20) containing 5% low fat milk for 1 h then incu-
bated with the following primary antibodies in block overnight
at 4 C [rabbit anti-Cep290, Abcam (ab85728) 1:1000; rabbit anti-
Cdk5, New England Biolabs (14145), 1:100; rabbit anti-GAPDH,
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Cell Signaling technology, 1:5000]. After washing in TBST, mem-
branes were incubated with fluorescently labelled secondary
antibodies (LI-COR) for 90 min at room temperature, washed
again in TBST and visualized with an Odyssey CLxVR imaging
system (LI-COR). Quantification was performed with Image stu-
dio software (LI-COR).
Scanning electron microscopy imaging
For SEM, samples were fixed overnight in 2% glutaraldehyde in
0.1 M Sorenson’s phosphate buffer, dehydrated through a
graded series of ethanol and critical-point dried (Baltec dryer).
They were coated with 10 nm of gold (Polaron coating unit) and
viewed on a Tescan Vega LMU SEM operated at 8–10 kV. Images
were captured and measured in a blinded fashion.
Immunofluorescence microscopy imaging
hURECs were fixed in 100% methanol for 10 min. Axoneme of
cilia was labelled with monoclonal mouse anti-alpha-acetylated
tubulin primary antibody (Sigma, T6793, 1:1000). Ciliary mem-
brane was labelled with rabbit anti-ARL13B (Proteintech, 17711-
1-AP). Commercial antibodies were used for detection of Cep162
(Atlas antibodies, rabbit polyclonal, HPA030170), pericentrin
(Abcam, rabbit polyclonal, ab4448) and IFT88 (Proteintech, rabbit
polyclonal, 13967-1-AP). Fluorescent secondary antibodies used
were donkey anti-mouse Alexa Fluor 594 (Thermo Fisher
Scientific, 1: 200) and donkey anti-rabbit FITC (Thermo Fisher
Scientific, 1: 200). Images and z-stacks were captured in a
blinded fashion, using the Carl Zeiss Axio Imager and Nikon
(A1) confocal inverted microscope.
siRNA knockdown experiments
hURECs (0.05  106) were transfected with 5 pmol Negative
Control siRNA (AM4611, ThermoFisher), siRNA targeting human
CDK5 (AM51331, ThermoFisher) or siRNA targeting human
CEP290 (AM16708, ThermoFisher), using Lipofectamine
RNAiMAX (ThermoFisher, 13778150) under manufacturer’s
instructions.
Purmorphamine and roscovitine treatments
hURECs were treated with 20 lM Purmorphamine (Merck-
Millipore)/0.2% DMSO (Sigma-Aldrich) treatment for 24 h before
analysis. hURECs were treated with 10 lM roscovitine (Sigma-
Aldrich) for 24 h before fixing and imaging as above. 0.2% DMSO
alone was used as a negative control.
Supplementary Material
Supplementary Material is available at HMG online.
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Table S1. Common variants identified in the two siblings. 
Patient
s 
Genomic 
position 
(GRCh37) 
Gene Gene name 
RefSeq 
accession 
Nt change 
c. 
AA change 
p. 
Polyphen
2 (score) 
Sift 
(score
) 
Hom/he
t 
Coverage 
ref/var      
(II:2; II:1) 
HGMD 
(gene/variant
) 
Disease 
ExAC 
(freq) 
Family 
JBTS 
Chr12:88496758 CEP290 
Centrosomal 
protein 
290KD NM_025114 c.2848dup 
p.Q950Pfs*
6 - - het 
(71/81) ; 
(64/154)  Yes/No ciliopathies - 
  
Chr12:88500452 CEP290 
Centrosomal 
protein 
290KD NM_025114 c.2817G>T p.K939N  0.771 0 het 
(137/125
) ; 
(79/202) Yes/No ciliopathies - 
  
Chr3:132403405 NPHP3 
Nephrocysti
n 3 NM_153240 
c.3563A>
G p.K1188R 0.336 0.23 het 
(73/99) ; 
(95/75) Yes/No 
Nephronophthisi
s 2/121110 
  
Chr1:220154795 EPRS 
Glutamyl-
Prolyl-TRNA 
Synthetase NM_004446 
c.3378G>
A p.M1126I 0.895 0 het 
(154/107) 
; (95/202) - - - 
  
Chr2:84775496 DNAH6 
Dynein 
Axonemal 
Heavy Chain 
6 NM_001370 
c.1271A>
G p.Y424C 0.976 0.01 het 
(109/110) 
; (76/163) Yes/No Heterotaxy 
11/12121
2 
  
Chr3:52424969 DNAH1 
Dynein 
Axonemal 
Heavy Chain 
1 NM_015512 
c.9640G>
A p.D3214N  0.999 0 het 
(23/32) ; 
(14/30) Yes/No 
Primary ciliary 
dyskinesia 1/22540 
  
Chr7:111617266 DOCK4 
Dedicator Of 
Cytokinesis 4 NM_014705 c.622A>G p.S208G 0.599 0.09 het 
(191/177) 
; 
(133/130) - - - 
  
Chr12:11269420
0 
HECTD
4 
HECT 
Domain E3 
Ubiquitin 
Protein 
Ligase 4 
NM_00110966
2 c.2819C>T p.T940M  0.293 0 het 
(132/121) 
; 
(106/190) - - - 
 
Genes written in bold letters indicate likely disease-causative variants. Columns from left to right: position of the variant in GRCh37 (genomic position), chromosome (Chr), 
name of the gene in which the variant is detected (Gene), RefSeq accession, nucleotide (Nt) and amino acid (AA) change, Polyphen 2 (PP2) and SIFT Score (red : predict 
disease causing, orange: intermediate, green: predict benign), homozygotes (hom) or heterozygotes (het) variants, number of reads whereby position is covered for 
reference allele (Ref) and variant allele (var), genes and variants reported in Biobase/HGMD and associated disease, allelic frequency in Exome Aggregation Consortium 
(ExAC).   
 
Table S2. Variants identified only in individual JBTS II:1 
 
 
Patie
nt 
Genomic 
position 
(GRCh37) 
Gene Gene name 
RefSeq 
accession 
Nt 
change c. 
AA 
change 
p. 
Polyphe
n2 
(score) 
Sift 
(scor
e) 
Hom/h
et 
Coverage 
ref/var (II:1) 
HGMD 
(gene/varia
nt) 
Disease 
ExAC 
(freq) 
JBTS 
II:1 
Chr6:389766
75 
DNAH
8 Dynein Axonemal Heavy Chain 8 
NM_001206
927 
c.13300C
>T 
p.R4434
W 1 0 het 
(91/110) 
(54%) Yes/No 
Primary 
ciliary 
dyskinesia 
35/1212
88 
  
Chr2:108455
304 RGPD4 
RANBP2-Like And GRIP Domain 
Containing 4 NM_182588 c.289G>C p.V97L  0.952 0 het 
(20/19) 
(48%) - - - 
  
Chr2:109379
793 
RANBP
2 RAN binding protein 2 NM_006267 
c.2798T>
C 
p.M933
T  0.321 0 het 
(103/91) 
(46%) Yes/No 
Acute 
necrotizing 
encephalopa
thy 
1/12074
8 
  
Chr14:23511
928 
PSMB
11 Proteasome Subunit Beta 11 
NM_001099
780 c.494G>A p.S165N 0.452 0.13 het 
(12/10) 
(45%) - - 
22/1198
92 
  
Chr15:91565
406 
VPS33
B Vacuolar protein sorting 13B NM_018668 c.74A>G p.Q25R 0.006  0.43 het 
(36/38) 
(51%) Yes/No 
Arthrogrypos
is-renal 
dysfunction-
cholestasis 
syndrome 0/23306 
  
Chr3:513787
17 DOCK3 Dedicator of cyto-kinesis 3 NM_004947 
c.3816C>
G 
p.D1272
E  0.005 0.3 het (6/8) (57%) Yes/No 
muscle 
hypotonia, 
ataxia, and 
intellectual 
disability 
47/1104
98 
 
Genes written in bold letters indicate likely disease-causative variants. Columns from left to right: position of the variant in GRCh37 (genomic position), chromosome (Chr), 
name of the gene in which the variant is detected (Gene), RefSeq accession, nucleotide (Nt) and amino acid (AA) change, Polyphen 2 (PP2) and SIFT Score (red : predict 
disease causing, orange: intermediate, green: predict benign), homozygotes (hom) or heterozygotes (het) variants, number of reads whereby position is covered for 
reference allele (Ref) and variant allele (var), genes and variants reported in Biobase/HGMD and associated disease, allelic frequency in Exome Aggregation Consortium 
(ExAC).  
 
 
 
 
Table S3. Variants identified only in individual JBTS II:2 
Patie
nt 
Genomic 
position 
(GRCh37) 
Gene Gene name 
RefSeq 
accession 
Nt change 
c. 
AA change p. 
Polyphe
n2 
(score) 
Sift 
(scor
e) 
Hom/h
et 
Coverage 
ref/var (II:2) 
HGM
D 
(gene
/varia
nt) 
Disease 
ExAC 
(freq) 
JBTS 
II:2 
Chr4:741240
72 
ANKRD
17 
Ankyrin Repeat Domain 
17 NM_032217 
c.303_314
del 
p.G107_G110
del - - het 
(49/41) 
(45%) - - 
2/12072
8 
  Chr3:480193
91 MAP4 
Microtubule-associated 
protein 4 NM_002375 c.256A>G p.N86D 0.703 0.12 het 
(56/69) 
(55%) 
Yes/N
o 
Seckel syndrome: 
growth retardation 
and normocephaly 
1/12140
0 
  
Chr15:86262
432 AKAP13 
A kinase (prka) anchor 
protein 13 NM_006738 c.6139G>A p.D2047N 0.998 0 het 
(153/152) 
(49%) - - 
51/1213
76 
  
Chr16:72229
3 RHOT2 
Ras Homolog Family 
Member T2 NM_138769 c.1235C>T p.T412M 0.998 0.01 het 
(93/98) 
(51%) - - 
89/1191
50 
  
Chr16:19552
027 CCP110 
Centriolar Coiled-Coil 
Protein 110 
NM_001199
022 c.1967G>A p.R656Q 0.928 0.08 het 
(212/191) 
(47%) - - 
81/1194
26 
  
Chr17:72741
040 RAB37   
NM_001163
989 c.476G>A p.R159H 0.871 0.01 het 
(132/177) 
(57%) - - 
33/1212
98 
  
Chr6:389415
67 DNAH8 
Dynein Axonemal Heavy 
Chain 8 
NM_001206
927 
c.12656G>
A p.R4219Q  0.001 0.05 het 
(64/58) 
(47%) 
Yes/N
o 
Primary ciliary 
dyskinesia 
20/1203
48 
  
Chr7:157202
588 DNAJB6 
DnaJ homologue, 
subfamily B, member 6 NM_058246 c.791G>A p.R264Q 0.059 0.69 het 
(32/14) 
(30%) 
Yes/N
o Myopathy - 
  
Chr8:124141
323 
TBC1D3
1 
TBC1 Domain Family 
Member 31 NM_145647 c.2135T>C p.M712T 0.050 0.01 het 
(135/115) 
(46%) - - 
3/12099
0 
  Chr9:124073
114 GSN Gelsolin NM_000177 c.657C>G p.D219E 0.875 0 het 
(87/65) 
(42%) 
Yes/N
o 
Familial Amyloidosis 
of Finnish type, 
nephrotic syndrome 
1/12051
4 
  
Chr15:42158
038 SPTBN5 
Spectrin, beta, non-
erythrocytic 5 NM_016642 c.6886C>T p.R2296W 0.019 0.01 het (14/5) (26%) 
Yes/N
o sacral agenesis 2/24600 
  
Chr22:50969
172 ODF3B 
Outer Dense Fiber Of 
Sperm Tails 3B 
NM_001014
440 c.650A>C p.K217T 0.142 0.03 het 
(62/48) 
(43%) - - 
18/9893
0 
 
Genes written in bold letters indicate likely disease-causative variants. Columns from left to right: position of the variant in GRCh37 (genomic position), chromosome (Chr), 
name of the gene in which the variant is detected (Gene), RefSeq accession, nucleotide (Nt) and amino acid (AA) change, Polyphen 2 (PP2) and SIFT Score (red : predict 
disease causing, orange: intermediate, green: predict benign), homozygotes (hom) or heterozygotes (het) variants, number of reads whereby position is covered for 
reference allele (Ref) and variant allele (var), genes and variants reported in Biobase/HGMD and associated disease, allelic frequency in Exome Aggregation Consortium 
(ExAC). 
  
 Figure S1: Ciliation rates and FACS analysis of wild type and patient hURECs in response to treatments 
(a) Percentage rates of ciliation in serum starved wild type (WT) and JBTS patient II:2 in control conditions and 
following treatment with Purmorphamine (Pur) and Roscovitine (Ros). There is a significant difference in 
percentage ciliated cells between WT and II:2 (* p<0.001, Unpaired Student’s t-test). Treatment of II:2 with Pur 
or Ros did not change percentage ciliation rates (n.s. not significant). 
(b) FACS analysis, using propidium iodide for DNA staining, of wild type (WT) and II:2 hURECs before and after 
treatment with Purmorphamine (Pur). II:2 cells are sensitive to Pur treatment with a reduction in percentage 
cycling cells. 
 
  
 Figure S2: Localisation of transition zone, centrosomal and ciliary proteins in wild type and patient JBTS II:2 
hURECs. 
Immunofluorescence images showing 
(a & b) Wild type and patient JBTS II:2 hURECs with maintained localisation of CEP162 (green), a transition 
zone protein. 
(c & d) Wild type and patient JBTS II:2 hURECs with maintained localisation of pericentrin (green), a 
centrosomal associated protein. 
(e & f) Wild type and patient JBTS II:2 hURECs with localisation of IFT88 (green), an axonemal protein. Cilia are 
localised with alpha-acetylated tubulin (red). Scale bar 5 µm. 
(g) Quantification of ciliary length measured by immunofluorescence imaging using antibodies towards alpha-
acetylated tubulin (Acet Tub) and IFT88. There is no significant (n.s. Paired Student's t-test) mismatch in ciliary 
length between these ciliary axonemal proteins. n numbers: WT cilia = 37, II:2 cilia = 49. 
(h) Table showing median cilia length of wild type and JBTS II:2 hURECs when measured by scanning electron 
microscopy (SEM), and immunofluorescence microscopy using antibodies directed towards alpha-acetylated 
tubulin (Acet Tub), ARL13B and IFT88. 
 
  
 
 
 
Figure S3: Pedigree, genetic, biochemical and ciliary phenotype data of family LCA 
(a) Pedigree diagram showing one affected male with isolated Leber congenital amaurosis (normal renal function 
and normal brain development (squares, males; circles females)). 
(b) Sequence chromatograms from II:2 showing compound heterozygous changes in CEP290 c.297+1G>T (predicted 
to affect splice donor site) and c.4661_4663delAAG; p.Q1554del. 
(c) Domain structure of CEP290 protein (2479 amino acids) with predicted coiled coil domains (CC) numbered and 
shown in yellow; tropomyosin homology domain (TM), RepA/Rep+ protein KID (KID); bipartite nuclear localization 
signal (NLS_BP); ATP/GTP-binding site motif A (P-loop). The extent of homology with SMC proteins is indicated by an 
orange bar. The predicted defects of CEP290 at amino acid positions 99 and 1554 are shown. 
(d) Western blot (cropped image) showing normal expression of full-length wild type CEP290 protein from hURECs 
derived from II:2 using a C-terminal directed CEP290 antibody. 
(e) Low power immunofluorescence images (ARL13B-green; DAPI-blue) of hURECs from unaffected sibling II:1 (scale 
bar = 20 µm). 
(f) Low power immunofluorescence images (ARL13B-green; DAPI-blue) of hURECs from affected sibling II:2 (scale bar 
= 20 µm). 
(g) Percentage ciliated hURECs (3 biological replicates) in unaffected II:1 (58%, n= 107) and affected LCA II:2 sibling 
(41%, n=61), n.s. not significant, Unpaired Student’s t-test. 
(h) High power immunofluorescence images (ARL13B-green; alpha-acetylated tubulin-red; DAPI-blue) of hURECs 
from unaffected sibling II:1 (scale bar = 5 µm). 
(i) Low power immunofluorescence images (ARL13B-green; DAPI-blue) of hURECs from affected sibling LCA II:2 (scale 
bar = 5 µm). 
(j) Dot plot with means of hUREC cilia length in unaffected sibling (II:1) (n= 54) and affected sibling LCA II:2 
(n=39), n.s. not significant, Unpaired Student’s t-test. 
 
 
  
  
 
Figure S4: Hh pathway manipulation of wild–type cilia in hURECs  
(a) SEM image of cilia from wild type hURECs (Scale bar 2 µm). 
(b) SEM images of cilia from wild type hURECs treated with Hh antagonist HPI-4 (Scale bar 2 µm). 
(c) Dot plot with means showing quantification of ciliary lengths following EM imaging. * p<0.001, Unpaired 
Student’s t-test. 
(d) Immunofluorescence imaging (alpha-acetylated tubulin red; ARL13B green) of cilia from wild type hURECs 
(scale bar 5 µm). 
(e) Immunofluorescence imaging (alpha-acetylated tubulin, red; ARL13B, green) of cilia from wild type hURECs 
treated with HPI-4 (Scale bar 5 µm). 
(f) Dot plot with means showing quantification of ciliary lengths following immunofluorescence imaging (Acet 
Tub, alpha-acetylated tubulin; n.s. not significant, *, p< 0.001, Unpaired Student’s t-test).  
  
 
 
 
Fig. S5: Response to treatments in II:2 hURECS and CEP290 depleted wild type hURECS 
(a) Dot plot with means to show quantification of cilia length using both alpha-acetylated tubulin (Acet Tub) 
and ARL13B in wild type (WT, n=48), wild type treated with roscovitine (WT + Ros, n=15), JBTS II:2 hURECs 
(n=48) and JBTS II:2 treated with roscovitine (Ros, n=34) treatment (n.s. not significant, * p<0.0001, Paired 
Student’s t- test). 
(b) Dot plots with means indicated to show the difference in cilia length of each cilia (data from panel a) as 
determined by the measuring axonemal length under immunofluorescence imaging using antibodies against 
alpha-acetylated tubulin (Acet Tub) and ARL13B. (n.s, not significant, Unpaired Student’s t-test) 
(c) Percentage rates of ciliation in serum starved wild type cells treated with control siRNA (siCTRL); siRNA 
CDK5, (siCDK5); siRNA CEP290 (siCEP290); siRNA CEP290 + Purmorphamine (siCEP290+Pur) and siRNA CEP290 
+ Roscovitine (siCEP290+Ros).  Experiments were performed in triplicate. The difference in percentage ciliation 
rates for siCTRL, siDCDK5, siCEP290 and following Pur or Ros treatment was not significant (n.s. ANOVA). 
(d) Low power images showing ciliation rates in wild type hURECs treated with control siRNA (siCTRL); siRNA 
CEP290 (siCEP290); siRNA CEP290 + purmorphamine (siCEP290+Pur) and siRNA CEP290 + roscovitine 
(siCEP290+Ros). Scale bar 10 µm.  
 
 
  
 
